Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Christian Hove Claussen"'
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 7, Pp 735-747 (2021)
Abstract Selatogrel is a potent and reversible P2Y12 receptor antagonist developed for subcutaneous self‐administration by patients with suspected acute myocardial infarction. After single‐dose emergency treatment with selatogrel, patients are sw
Externí odkaz:
https://doaj.org/article/db3892d181f343de96077aaa40114173
Autor:
Frantisek Hubálek, Hanne H. F. Refsgaard, Sanne Gram-Nielsen, Peter Madsen, Erica Nishimura, Martin Münzel, Christian Lehn Brand, Carsten Enggaard Stidsen, Christian Hove Claussen, Erik Max Wulff, Lone Pridal, Ulla Ribel, Jonas Kildegaard, Trine Porsgaard, Eva Johansson, Dorte Bjerre Steensgaard, Lars Hovgaard, Tine Glendorf, Bo Falck Hansen, Maja Kirkegaard Jensen, Peter Kresten Nielsen, Svend Ludvigsen, Susanne Rugh, Patrick W. Garibay, Mary Courtney Moore, Alan D. Cherrington, Thomas Kjeldsen
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-9 (2020)
Recently, the first orally-administered ultra-long acting insulin was shown to have clinical efficacy. Here, the authors report the molecular engineering, as well as the biological and pharmacological properties of these insulin analogues.
Externí odkaz:
https://doaj.org/article/b3637544155945e480839f9c67516402
Autor:
Frantisek Hubálek, Hanne H. F. Refsgaard, Sanne Gram-Nielsen, Peter Madsen, Erica Nishimura, Martin Münzel, Christian Lehn Brand, Carsten Enggaard Stidsen, Christian Hove Claussen, Erik Max Wulff, Lone Pridal, Ulla Ribel, Jonas Kildegaard, Trine Porsgaard, Eva Johansson, Dorte Bjerre Steensgaard, Lars Hovgaard, Tine Glendorf, Bo Falck Hansen, Maja Kirkegaard Jensen, Peter Kresten Nielsen, Svend Ludvigsen, Susanne Rugh, Patrick W. Garibay, Mary Courtney Moore, Alan D. Cherrington, Thomas Kjeldsen
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-1 (2020)
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Externí odkaz:
https://doaj.org/article/f3cf07c418ea4af69c46d62c9eb076b7
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 7, Pp 735-747 (2021)
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology
Selatogrel is a potent and reversible P2Y12 receptor antagonist developed for subcutaneous self‐administration by patients with suspected acute myocardial infarction. After single‐dose emergency treatment with selatogrel, patients are switched to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ffc3d121fb9635500498017e79266b4
https://doaj.org/article/db3892d181f343de96077aaa40114173
https://doaj.org/article/db3892d181f343de96077aaa40114173
Autor:
Antonio Curti, Alessandro Rambaldi, Chiara Cattaneo, Roberto Cairoli, Matteo Della Porta, Patrizia Chiusolo, Federico Lussana, Marta Ubezio, Valentina Mancini, Isabel Cano, Carmen Besliu, Christian Hove Claussen, Rosalinda Gatto, Patrizia Crivori, Elena Colajori, Alessio Somaschini, Cristina Davite, Antonella Isacchi, Elena Ardini, Lisa Mahnke, Pau Montesinos
Publikováno v:
Cancer Research. 83:CT025-CT025
Background: FLT3 mutations occur in approximately 30% of AML patients and are associated with aggressive disease. Despite the approval of midostaurin and gilteritinib, the prognosis for FLT3+ patients with relapsed or refractory disease is poor. NMS-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::43d48a1f741b4b971e7c6c7afb0818fe
https://doi.org/10.1158/1538-7445.am2023-ct025
https://doi.org/10.1158/1538-7445.am2023-ct025
Autor:
Erik M. Wulff, Patrick William Garibay, Eva Johansson, Martin Münzel, Tine Glendorf, Erica Nishimura, Bo Falck Hansen, Thomas Kjeldsen, Peter Madsen, Christian L. Brand, Sanne Gram-Nielsen, Trine Porsgaard, Hanne H. F. Refsgaard, Frantisek Hubalek, Svend Ludvigsen, Dorte Bjerre Steensgaard, Lars Hovgaard, Carsten Enggaard Stidsen, Susanne Rugh, Jonas Kildegaard, Lone Pridal, Maja Jensen, Christian Hove Claussen, Ulla Ribel, Alan D. Cherrington, Mary Courtney Moore, Peter Kresten Nielsen
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-9 (2020)
Nature Communications
Nature Communications
Recently, the clinical proof of concept for the first ultra-long oral insulin was reported, showing efficacy and safety similar to subcutaneously administered insulin glargine. Here, we report the molecular engineering as well as biological and pharm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::113155943c2b6a189cde64bb824cd5b9
https://doaj.org/article/b3637544155945e480839f9c67516402
https://doaj.org/article/b3637544155945e480839f9c67516402
Autor:
Ulla Ribel, Erik M. Wulff, Alan D. Cherrington, Peter Kresten Nielsen, Martin Münzel, Thomas Kjeldsen, Svend Ludvigsen, Frantisek Hubalek, Lars Hovgaard, Christian Hove Claussen, Jonas Kildegaard, Maja Jensen, Lone Pridal, Hanne H. F. Refsgaard, Patrick William Garibay, Mary Courtney Moore, Sanne Gram-Nielsen, Erica Nishimura, Dorte Bjerre Steensgaard, Carsten Enggaard Stidsen, Tine Glendorf, Peter Madsen, Susanne Rugh, Bo Falck Hansen, Eva Johansson, Christian L. Brand, Trine Porsgaard
Publikováno v:
Nature Communications
Nature Communications, Vol 11, Iss 1, Pp 1-1 (2020)
Nature Communications, Vol 11, Iss 1, Pp 1-1 (2020)
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6582242c3083f360c87f02dd8695f95
http://europepmc.org/articles/PMC7441397
http://europepmc.org/articles/PMC7441397